相关实验视频

Updated: Jan 18, 2026

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

通过综合网络毒理学分析和实验验证,评估PET-MP暴露对动脉样硬化的毒理学影响

Cong Yan¹, Tianming Liu²

¹The First Affiliated Hospital of Harbin Medical University, Harbin, 150001, China.

Naunyn-Schmiedeberg's archives of pharmacology

|January 16, 2026

概括

聚乙烯四甲酸微塑料 (PET-MPs) 可能通过促进炎症,导致动脉样硬化 (AS). 这项研究使用生物信息学和实验方法确定了涉及PET-MP诱导的AS的四个核心目标 (CCL5,CTSB,PPARG,TNF).

科学领域:

环境毒理学环境毒理学
心血管研究研究心血管研究
分子生物学分子生物学

背景情况:

聚乙烯四甲酸微塑料 (PET-MPs) 可以进入人体.
连接PET-MPs与动脉样硬化 (AS) 的确切毒理机制尚未完全理解.

研究的目的:

阐明PET-MPs在诱导动脉样硬化的毒理机制.
确定涉及PET-MP诱导的AS的潜在分子标.

主要方法:

利用生物信息学方法,包括目标识别 (ChEMBL,SwissTargetPrediction,SEA,PharmMapper),基因丰富分析和蛋白质与蛋白质相互作用网络.
来自GEO数据库的综合RNA-seq和单细胞RNA测序数据.
进行了分子对接 (AutoDock Vina) 和实验验证 (细胞实验,PCR).

主要成果:

确定了PET-MP诱导的AS的41个潜在目标,随后又确定了四个核心目标 (CCL5,CTSB,PPARG,TNF).
核心标基因表达显示了动脉样硬化斑块中的细胞异质性.
PET-MPs表现出对核心点的亲和力,并且在细胞实验中被发现促进炎症反应,这表明它在AS恶化中的作用.

结论:

通过多种信号通路,PET-MPs可能会诱导AS,主要是通过促进炎症反应.
这项研究提供了对PET-MPs在AS病变发生过程中的毒理机制的初步见解.
强调需要进一步调查与PET-MP暴露相关的健康风险.

关键词:

在 AS AS AS AS AS 里面.分子对接是分子对接.网络毒理学网络毒理学有关PET-MPs的相关信息

更多相关视频

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease

Published on: January 7, 2014

相关概念视频

Toxic Reactions: Overview

Toxic Reactions: Overview

When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...